The estimated Net Worth of Uma Sinha is at least $14.8 million dollars as of 13 January 2021. Uma Sinha owns over 10,000 units of BridgeBio Pharma Inc stock worth over $8,579,635 and over the last 6 years he sold BBIO stock worth over $3,504,025. In addition, he makes $2,750,940 as Chief Scientific Officer at BridgeBio Pharma Inc.
Sign up
Uma Sinha BBIO stock SEC Form 4 insiders trading
Uma has made over 11 trades of the BridgeBio Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of BBIO stock worth $1,243,200 on 13 January 2021.
The largest trade he's ever made was buying 14,000 units of BridgeBio Pharma Inc stock on 1 July 2019 worth over $238,000. On average, Uma trades about 3,820 units every 35 days since 2018. As of 13 January 2021 he still owns at least 306,525 units of BridgeBio Pharma Inc stock.
You can see the complete history of Uma Sinha stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Uma Sinha biography
Dr. Uma Sinha Ph.D. serves as Chief Scientific Officer of the Company. Prior to that, Dr. Sinha served as chief scientific officer of Global Blood Therapeutics, Inc. (Nasdaq: GBT), a clinical stage biopharmaceutical company, from 2014 to 2015 and previously as senior vice president of research from 2013 to 2014. She was vice president, head of biology at Portola Pharmaceuticals, Inc. (Nasdaq: PTLA), a clinical stage biotechnology company, from 2010 to 2012 and was the vice president of translational biology from 2004 to 2010. Previously, Dr. Sinha held senior research positions at Millennium Pharmaceuticals, Inc., a biopharmaceutical company, and COR Therapeutics, Inc., a biopharmaceutical company. Dr. Sinha received her Ph.D. in biochemistry from the University of Georgia and her B.Sc. with honors in chemistry from Presidency College.
What is the salary of Uma Sinha?
As the Chief Scientific Officer of BridgeBio Pharma Inc, the total compensation of Uma Sinha at BridgeBio Pharma Inc is $2,750,940. There are 2 executives at BridgeBio Pharma Inc getting paid more, with Neil Kumar having the highest compensation of $26,334,100.
How old is Uma Sinha?
Uma Sinha is 63, he's been the Chief Scientific Officer of BridgeBio Pharma Inc since 2016. There are 6 older and 16 younger executives at BridgeBio Pharma Inc. The oldest executive at BridgeBio Pharma Inc is Dr. Charles J. Homcy M.D., 73, who is the Chairman of Pharmaceuticals & Lead Director.
What's Uma Sinha's mailing address?
Uma's mailing address filed with the SEC is C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2000, SAN FRANCISCO, CA, 94104.
Insiders trading at BridgeBio Pharma Inc
Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo et Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.
What does BridgeBio Pharma Inc do?
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
What does BridgeBio Pharma Inc's logo look like?
Complete history of Uma Sinha stock trades at Eidos Therapeutics Inc et BridgeBio Pharma Inc
BridgeBio Pharma Inc executives and stock owners
BridgeBio Pharma Inc executives and other stock owners filed with the SEC include:
-
Neil Kumar,
Chief Executive Officer, Director -
Charles Homcy,
Chairman of Pharmaceuticals, Lead Director -
Uma Sinha,
Chief Scientific Officer -
Brian Stephenson,
Chief Financial Officer -
Eric Aguiar,
Independent Director -
Ali Satvat,
Independent Director -
Jennifer Cook,
Independent Director -
Dr. Neil Kumar Ph.D.,
Co-Founder, CEO & Director -
Dr. Brian C. Stephenson C.F.A., Ph.D.,
CFO, Sec. & Principal Accounting Officer -
James Momtazee,
Independent Director -
Richard Scheller,
Chairman of Research and Development, Director -
Dr. Michael Thomas Henderson M.D.,
Chief Bus. Officer -
Dr. Charles J. Homcy M.D.,
Chairman of Pharmaceuticals & Lead Director -
Dr. Richard H. Scheller Ph.D.,
Chairman of R&D and Director -
Dr. Cameron Turtle DPHIL, Ph.D.,
Chief Strategy Officer -
Randal Scott,
Independent Director -
Brenton Saunders,
Independent Director -
Andrew Lo,
Independent Director -
Ronald Daniels,
Independent Director -
Michael Henderson,
Chief Business Officer -
Cameron Turtle,
Senior Vice President - Portfolio Management and Corporate Development -
Frank Mccormick,
Chairman of Oncology -
Dr. Frank McCormick Ph.D.,
Chairman of Oncology -
Grace Rauh,
VP of Communications -
Dr. Uma Sinha Ph.D.,
Chief Scientific Officer -
Yi Ching Yau,
Chief Accounting Officer -
Genetic Disorder L.P.Kkr Ge...,
-
Management Holdings L.P.Kkr...,
-
Douglas A. Dachille,
-
Fred Hassan,
-
Global Performance Llc Viki...,
-
Global Investors Lp Viking ...,
-
Genetic Disorder L.P.Robert...,
-
Yi Ching Yau,
Chief Accounting Officer -
Brian M. Stolz,
Chief Operating Officer -
Hannah Valantine,
-
Brent L Saunders,
Director -
Andrea Ellis,
-
Global Investors Lp Viking ...,
-
Thomas Trimarchi,
President and COO